This case report describes polymyxin B-immobilized fiber (PMX-F) treatment of septic shock caused by pyelonephritis in a 68-year-old woman with autosomal dominant polycystic kidney disease. She was admitted for severe lower left abdominal pain, high fever (40°C) and gross hematuria. Her endotoxin and high-mobility group box-1 protein (HMGB1) levels were extremely elevated. Her blood pressure was 68/36 mm Hg. Urinalysis revealed innumerable white blood cells (WBCs). Blood and urine cultures were positive for Klebsiella pneumoniae and Pseudomonas aeruginosa. Plain abdominal radiography showed large kidney shadows and calcium deposition. Septic shock with endotoxemia was diagnosed. Her symptoms of septic shock persisted for 3 days with antibiotics, γ-globulin and dopamine. Direct hemoperfusion was performed twice with a PMX-F column. The patient’s body temperature, WBC count and C-reactive protein level decreased. Her blood endotoxin level and blood HMGB1 level also decreased to an almost normal level. She was discharged on day 23 after admission.

Keywords:
Polymyxin B-immobilized fiber, Autosomal dominant polycystic kidney disease, Endotoxin, High-mobility group box-1 protein, Sepsis
1.
Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systemic review. Crit Care 2007;11:R47.
2.
Shoji H: Extracorporeal endotoxin removed for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003;7:108–114.
3.
Yamada S, Maruyama I: HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007;375:36–42.
4.
Sakamoto Y, Mashiko K, Matsumoto H, Hara Y, Kutsukawa N, Yamamoto Y: Relationship between effect of polymyxin B-immobilized fiber and high-mobility group box-1 protein in septic shock patients. ASAIO J 2007;53:324–328.
5.
Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, Bollaert PE: High-mobility group box-1 protein plasma concentrations during septic shock. Int Care Med 2007;33:1347–1353.
6.
Sakamoto Y, Mashiko K, Matsumoto H, Hara Y, Kutsukawa N, Takei K, Ueno Y, Tomita Y, Yamamoto Y: Effect of direct hemoperfusion with a polymyxin B-immobilized fiber column on high mobility group box-1 (HMGB1) in severe septic shock: report of a case. ASAIO J 2006;52:e37–e39.
7.
Ravine D, Gibson RN, Walker RG, Shefield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease. Lancet 1994;343:824–827.
8.
Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994;167:412–417.
9.
Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I: New high mobility group box 1 assay system. Clin Chim Acta 2006;372:173–178.
10.
Nakamura T, Kawagoe Y, Matsuda T, Koide H: Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intens Care Med 2004;30:1838–1841.
11.
Nakamura T, Suzuki T, Kawagoe Y, Koide H: Polymyxin B-immobilized fiber hemoperfusion attenuates increased plasma atrial natriuretic peptide and brain natriuretic peptide levels in patients with septic shock. ASAIO J 2008;54:210–213.
12.
Torres VE, Rossetti S, Harris PC: Update on autosomal dominant polycystic kidney disease. Minerva Med 2007;98:669–691.
13.
Gupta S, Seith A, Sud K, Kohli HS, Singh SK, Sakhaja V, Suri S: CT in the evaluation of complicated autosomal dominant polycystic kidney disease. Acta Radiol 2000;41:280–284.
14.
Wang H, Li W, Goldstein R, Tracey KJ, Sama AE: HMGB1 as a potential therapeutic target. Novartis Found Symp 2007;280:73–85.
15.
Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I: Plasma concentrations and importance of high mobility group box protein in the progress of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005;94:975–979.
16.
Nakamura T, Kawagoe Y, Suzuki T, Shoji H, Ueda Y, Kobayashi N, Koide H: Changes in plasma IL-18 by direct hemoperfusion with polymyxin B-immobilized fiber in patients with septic shock. Blood Purif 2005;23:417–422.
17.
Kanesaka S, Sasaki J, Kuzume M. Narihara K, Takahashi Y: Effect of direct hemoperfusion using polymyxin B immobilized fiber on inflammatory mediators in patients with severe sepsis and septic shock. Int J Artif Organs 2008;31:891–897.
18.
Kumagai T, Takeyama N, Yabuki T, Harada M, Miki Y, Kanou H, Inoue S, Nakagawa T, Noguchi H: Apheresis of activated leukocytes with an immobilized polymyxin B filter in patients with septic shock. Shock 2010;34:461–466.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.